GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » EV-to-EBIT

PharmX Technologies (ASX:PHX) EV-to-EBIT : 236.06 (As of Jul. 19, 2025)


View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PharmX Technologies's Enterprise Value is A$49.57 Mil. PharmX Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.21 Mil. Therefore, PharmX Technologies's EV-to-EBIT for today is 236.06.

The historical rank and industry rank for PharmX Technologies's EV-to-EBIT or its related term are showing as below:

ASX:PHX' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.04   Med: 20.53   Max: 236.06
Current: 236.06

During the past 13 years, the highest EV-to-EBIT of PharmX Technologies was 236.06. The lowest was -36.04. And the median was 20.53.

ASX:PHX's EV-to-EBIT is ranked worse than
98% of 449 companies
in the Healthcare Providers & Services industry
Industry Median: 17.62 vs ASX:PHX: 236.06

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PharmX Technologies's Enterprise Value for the quarter that ended in Dec. 2024 was A$40.00 Mil. PharmX Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.21 Mil. PharmX Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 0.53%.


PharmX Technologies EV-to-EBIT Historical Data

The historical data trend for PharmX Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmX Technologies EV-to-EBIT Chart

PharmX Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.30 30.61 40.26 -14.03 40.36

PharmX Technologies Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -14.03 - 40.36 -

Competitive Comparison of PharmX Technologies's EV-to-EBIT

For the Health Information Services subindustry, PharmX Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmX Technologies's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's EV-to-EBIT falls into.


;
;

PharmX Technologies EV-to-EBIT Calculation

PharmX Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=49.572/0.21
=236.06

PharmX Technologies's current Enterprise Value is A$49.57 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmX Technologies  (ASX:PHX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PharmX Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=0.21/39.995518
=0.53 %

PharmX Technologies's Enterprise Value for the quarter that ended in Dec. 2024 was A$40.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmX Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmX Technologies Business Description

Traded in Other Exchanges
N/A
Address
17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.